Drug Trial Radar · NCT00810693
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
445
Actual
Start
Dec 17, 2008
Primary completion
May 14, 2012
Study completion May 14, 2012
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).
Conditions
- Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)Drug
BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
Riociguat (Adempas, BAY63-2521)Drug
BAY63-2521: 1.5mg tid orally for 12 weeks
PlaceboDrug
Matching Placebo tid orally for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12Time frame: Baseline and week 12
Locations
122 sites in 30 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
Aurora, Colorado
Site not named
Louisville, Kentucky
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Omaha, Nebraska
Site not named
New York, New York
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Fairfield, Ohio
Site not named
Providence, Rhode Island
Site not named
Dallas, Texas
Site not named
El Paso, Texas
Site not named
Houston, Texas
Site not named
Capital Federal, Argentina
Site not named
Darlinghurst, New South Wales, Australia
Site not named
New Lambton Heights, New South Wales, Australia
Site not named
Auchenflower, Queensland, Australia
Site not named
Herston, Queensland, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Site not named
Prahran, Victoria, Australia
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Linz, Upper Austria, Austria
Site not named
Bruxelles - Brussel, Belgium
Site not named
Leuven, Belgium
Site not named
Rio de Janeiro, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Calgary, Alberta, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Shanghai, China
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.